AMYPAD

Amyloid imaging to prevent Alzheimer’s disease
AMYPAD logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115952

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
11 999 886
EFPIA in kind
12 233 950
Other
3 095 452
Total Cost
27 329 288

Summary

Deposits of beta amyloid protein in the brain are a common sign of Alzheimer’s disease. AMYPAD will study the value of using positron emission tomography (PET) imaging to scan people’s brains for beta amyloid deposits. AMYPAD will carry out beta amyloid PET imaging on an unprecedented number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. AMYPAD will work closely with IMI’s EPAD project, which is working to increase our understanding of the early stages of dementia and creating a platform to test treatments designed to prevent dementia.

Participants Show participants on map

EFPIA companies
  • Ge Healthcare Limited, Little Chalfont, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Life Molecular Imaging LTD, Havant, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France
  • Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain
  • Karolinska Institutet, Stockholm, Sweden
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • Stichting Vumc, Amsterdam, Netherlands
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universite De Geneve, Genève 4, Switzerland
  • University College London, London, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ixico Technologies Limited, London, United Kingdom
  • Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg

CONTACT

Project coordinator
Frederik BARKHOF
STICHTING VUMC
f.barkhof[at]vumc.nl
Project contact
info[at]amypad.org
Project leader
Kate LAWMAN
GE Healthcare
kate.lawman[at]ge.com
Project co-leader
Serge VAN DER GEYTEN
JANSSEN
SVDGEYTE[at]its.jnj.com